Skip to Main Content

David Speicher, Ph.D.

David W. Speicher, Ph.D.


The Speicher Laboratory


Professor and Program Co-Leader, Molecular & Cellular Oncogenesis Program, The Wistar Institute Cancer Center

Director, Center for Systems & Computational Biology

Member, The Wistar Institute Melanoma Research Center

Scientific Director, Proteomics & Metabolomics Facility

About the Scientist

Speicher is a recognized leader in the field of proteomics, the systematic study of the full set of proteins produced by a given cell, tissue, or organism.

Speicher joined Wistar in 1986 from the Yale University School of Medicine. He was born and raised in Pennsylvania and attended Pennsylvania State University as both an undergraduate and graduate biochemistry student.  He received his Ph.D. in 1977 and subsequently pursued postdoctoral training at the Yale University School of Medicine.  He then accepted a position on the Yale Medical School research faculty with a joint appointment as the Director of Yale’s Protein Chemistry Laboratory, prior to moving to Wistar.

View Publications

The Speicher Laboratory

Using state-of-the-art high-resolution mass spectrometry with related experimental and computational methods, the Speicher laboratory investigates protein, polar metabolite and lipid changes associated with cancer and other clinical disorders.


Research Assistants

Lynn Beer
Sandra Harper
Peter Hembach


Learn more about current research in the Speicher laboratory

View PDF

The Speicher laboratory is pursuing three major projects as well as a number of collaborative projects in diverse biomedical research areas. Most studies utilize proteomics, lipidomics and metabolomics using mass spectrometry as a major tool.


Selected Publications

Agarwal, E., Altman, B.J., Ho Seo, J., Bertolini, I., Ghosh, J.C., Kaur, A., Kossenkov, A.V., Languino, L.R., Gabrilovich, D.I., Speicher, D.W., et al. “Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis.” Mol Cell Biol. 2019 May 6. pii: MCB.00109-19. doi: 10.1128/MCB.00109-19. [Epub ahead of print]

Nacarelli, T., Lau, L., Fukumoto, T., Zundell, J., Fatkhutdinov, N., Wu, S., Aird, K.M., Iwasaki, O., Kossenkov, A.V., Schultz, D., et al. “NAD+ metabolism governs the proinflammatory senescence-associated secretome.” Nat Cell Biol. 2019 Mar;21(3):397-407. doi: 10.1038/s41556-019-0287-4. Epub 2019 Feb 18.

Rebecca, V.W., Nicastri, M.C., Fennelly, C., Chude, C.I., Barber-Rotenberg, J.S., Ronghe, A., McAfee, Q., McLaughlin, N.P., Zhang, G., Goldman, A.R., et al. “PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.” Cancer Discov. 2019 Feb;9(2):220-229. doi: 10.1158/2159-8290.CD-18-0706. Epub 2018 Nov 15.

Singha, B., Harper, S.L., Goldman, A.R., Bitler, B.G., Aird, K.M., Borowsky, M.E., Cadungog, M.G., Liu, Q., Zhang, R., Jean, S., Drapkin, R., Speicher, D.W., et al. “CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer.” Sci Rep. 2018 Oct 3;8(1):14725. doi: 10.1038/s41598-018-32885-2.

Goldman, A.R., Bitler, B.G., Schug, Z., Conejo-Garcia, J.R., Zhang, R., Speicher, D.W., et al. "The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level." Mol Cell Proteomics. 2016 Nov;15(11):3348-3360. Epub 2016 Sep 21.

View Additional Publications